nodes	percent_of_prediction	percent_of_DWPC	metapath
Chlorpromazine—HRH4—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.027	0.027	CbGpPWpGaD
Chlorpromazine—HRH4—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0215	0.0215	CbGpPWpGaD
Chlorpromazine—DRD5—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0165	0.0165	CbGpPWpGaD
Chlorpromazine—HRH4—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0163	0.0163	CbGpPWpGaD
Chlorpromazine—ABCB1—Allograft Rejection—CXCL11—nasal cavity cancer	0.0154	0.0154	CbGpPWpGaD
Chlorpromazine—DRD4—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0153	0.0153	CbGpPWpGaD
Chlorpromazine—DRD3—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0136	0.0136	CbGpPWpGaD
Chlorpromazine—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0128	0.0128	CbGpPWpGaD
Chlorpromazine—HTR7—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0127	0.0127	CbGpPWpGaD
Chlorpromazine—DRD5—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0126	0.0126	CbGpPWpGaD
Chlorpromazine—DRD4—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0122	0.0122	CbGpPWpGaD
Chlorpromazine—HTR1A—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0119	0.0119	CbGpPWpGaD
Chlorpromazine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0116	0.0116	CbGpPWpGaD
Chlorpromazine—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.011	0.011	CbGpPWpGaD
Chlorpromazine—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0108	0.0108	CbGpPWpGaD
Chlorpromazine—DRD2—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0104	0.0104	CbGpPWpGaD
Chlorpromazine—CHRM2—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0101	0.0101	CbGpPWpGaD
Chlorpromazine—HTR6—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00971	0.00971	CbGpPWpGaD
Chlorpromazine—HTR7—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0097	0.0097	CbGpPWpGaD
Chlorpromazine—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00944	0.00944	CbGpPWpGaD
Chlorpromazine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00939	0.00939	CbGpPWpGaD
Chlorpromazine—ADRA2A—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.00933	0.00933	CbGpPWpGaD
Chlorpromazine—DRD4—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00929	0.00929	CbGpPWpGaD
Chlorpromazine—HRH4—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00923	0.00923	CbGpPWpGaD
Chlorpromazine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00899	0.00899	CbGpPWpGaD
Chlorpromazine—HTR2B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00887	0.00887	CbGpPWpGaD
Chlorpromazine—HRH4—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00838	0.00838	CbGpPWpGaD
Chlorpromazine—DRD1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00836	0.00836	CbGpPWpGaD
Chlorpromazine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00829	0.00829	CbGpPWpGaD
Chlorpromazine—DRD3—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00825	0.00825	CbGpPWpGaD
Chlorpromazine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00816	0.00816	CbGpPWpGaD
Chlorpromazine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00814	0.00814	CbGpPWpGaD
Chlorpromazine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00811	0.00811	CbGpPWpGaD
Chlorpromazine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00809	0.00809	CbGpPWpGaD
Chlorpromazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00801	0.00801	CbGpPWpGaD
Chlorpromazine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00799	0.00799	CbGpPWpGaD
Chlorpromazine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00742	0.00742	CbGpPWpGaD
Chlorpromazine—CALM3—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00723	0.00723	CbGpPWpGaD
Chlorpromazine—HTR1A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00719	0.00719	CbGpPWpGaD
Chlorpromazine—HTR2C—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00715	0.00715	CbGpPWpGaD
Chlorpromazine—DRD5—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00711	0.00711	CbGpPWpGaD
Chlorpromazine—CALM1—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00699	0.00699	CbGpPWpGaD
Chlorpromazine—CALM2—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00699	0.00699	CbGpPWpGaD
Chlorpromazine—ADRA1B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00685	0.00685	CbGpPWpGaD
Chlorpromazine—CALM3—Downstream signal transduction—FRS2—nasal cavity cancer	0.00679	0.00679	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling by FGFR—FRS2—nasal cavity cancer	0.00676	0.00676	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00673	0.00673	CbGpPWpGaD
Chlorpromazine—CALM3—DAP12 signaling—FRS2—nasal cavity cancer	0.00669	0.00669	CbGpPWpGaD
Chlorpromazine—CALM2—Downstream signal transduction—FRS2—nasal cavity cancer	0.00657	0.00657	CbGpPWpGaD
Chlorpromazine—CALM1—Downstream signal transduction—FRS2—nasal cavity cancer	0.00657	0.00657	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling by FGFR—FRS2—nasal cavity cancer	0.00654	0.00654	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling by FGFR—FRS2—nasal cavity cancer	0.00654	0.00654	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00651	0.00651	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00651	0.00651	CbGpPWpGaD
Chlorpromazine—CALM1—DAP12 signaling—FRS2—nasal cavity cancer	0.00648	0.00648	CbGpPWpGaD
Chlorpromazine—CALM2—DAP12 signaling—FRS2—nasal cavity cancer	0.00648	0.00648	CbGpPWpGaD
Chlorpromazine—DRD5—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00646	0.00646	CbGpPWpGaD
Chlorpromazine—DRD2—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00631	0.00631	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0063	0.0063	CbGpPWpGaD
Chlorpromazine—CALM3—DAP12 interactions—FRS2—nasal cavity cancer	0.0063	0.0063	CbGpPWpGaD
Chlorpromazine—CALM3—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.0063	0.0063	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling by EGFR—FRS2—nasal cavity cancer	0.00624	0.00624	CbGpPWpGaD
Chlorpromazine—HTR2A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00621	0.00621	CbGpPWpGaD
Chlorpromazine—HRH1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0062	0.0062	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00619	0.00619	CbGpPWpGaD
Chlorpromazine—CHRM1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00618	0.00618	CbGpPWpGaD
Chlorpromazine—CHRM3—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00616	0.00616	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling by PDGF—FRS2—nasal cavity cancer	0.00616	0.00616	CbGpPWpGaD
Chlorpromazine—CHRM2—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0061	0.0061	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00609	0.00609	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00609	0.00609	CbGpPWpGaD
Chlorpromazine—CALM2—DAP12 interactions—FRS2—nasal cavity cancer	0.00609	0.00609	CbGpPWpGaD
Chlorpromazine—CALM1—DAP12 interactions—FRS2—nasal cavity cancer	0.00609	0.00609	CbGpPWpGaD
Chlorpromazine—CALM2—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00609	0.00609	CbGpPWpGaD
Chlorpromazine—CALM1—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00609	0.00609	CbGpPWpGaD
Chlorpromazine—ADRA1A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00608	0.00608	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling by EGFR—FRS2—nasal cavity cancer	0.00604	0.00604	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling by EGFR—FRS2—nasal cavity cancer	0.00604	0.00604	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00598	0.00598	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00598	0.00598	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling by PDGF—FRS2—nasal cavity cancer	0.00596	0.00596	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling by PDGF—FRS2—nasal cavity cancer	0.00596	0.00596	CbGpPWpGaD
Chlorpromazine—CALM3—B Cell Activation—FRS2—nasal cavity cancer	0.00583	0.00583	CbGpPWpGaD
Chlorpromazine—ADRA2A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00565	0.00565	CbGpPWpGaD
Chlorpromazine—CALM2—B Cell Activation—FRS2—nasal cavity cancer	0.00564	0.00564	CbGpPWpGaD
Chlorpromazine—CALM1—B Cell Activation—FRS2—nasal cavity cancer	0.00564	0.00564	CbGpPWpGaD
Chlorpromazine—CALM3—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00558	0.00558	CbGpPWpGaD
Chlorpromazine—HTR6—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00549	0.00549	CbGpPWpGaD
Chlorpromazine—HTR7—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00548	0.00548	CbGpPWpGaD
Chlorpromazine—CALM2—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.0054	0.0054	CbGpPWpGaD
Chlorpromazine—CALM1—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.0054	0.0054	CbGpPWpGaD
Chlorpromazine—DRD4—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00525	0.00525	CbGpPWpGaD
Chlorpromazine—HTR2B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00501	0.00501	CbGpPWpGaD
Chlorpromazine—HTR6—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00499	0.00499	CbGpPWpGaD
Chlorpromazine—HTR7—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00498	0.00498	CbGpPWpGaD
Chlorpromazine—HRH4—Signaling Pathways—CXCL11—nasal cavity cancer	0.00495	0.00495	CbGpPWpGaD
Chlorpromazine—DRD4—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00477	0.00477	CbGpPWpGaD
Chlorpromazine—DRD1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00473	0.00473	CbGpPWpGaD
Chlorpromazine—DRD3—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00466	0.00466	CbGpPWpGaD
Chlorpromazine—HTR2B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00455	0.00455	CbGpPWpGaD
Chlorpromazine—DRD1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00429	0.00429	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling by NGF—FRS2—nasal cavity cancer	0.00429	0.00429	CbGpPWpGaD
Chlorpromazine—DRD3—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00423	0.00423	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling by NGF—FRS2—nasal cavity cancer	0.00415	0.00415	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling by NGF—FRS2—nasal cavity cancer	0.00415	0.00415	CbGpPWpGaD
Chlorpromazine—HTR1A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00406	0.00406	CbGpPWpGaD
Chlorpromazine—HTR2C—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00404	0.00404	CbGpPWpGaD
Chlorpromazine—ADRA1B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00387	0.00387	CbGpPWpGaD
Chlorpromazine—DRD5—Signaling Pathways—CXCL11—nasal cavity cancer	0.00382	0.00382	CbGpPWpGaD
Chlorpromazine—HTR1A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00369	0.00369	CbGpPWpGaD
Chlorpromazine—HTR2C—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00367	0.00367	CbGpPWpGaD
Chlorpromazine—DRD2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00357	0.00357	CbGpPWpGaD
Chlorpromazine—ADRA1B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00351	0.00351	CbGpPWpGaD
Chlorpromazine—HTR2A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00351	0.00351	CbGpPWpGaD
Chlorpromazine—HRH1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0035	0.0035	CbGpPWpGaD
Chlorpromazine—CHRM1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00349	0.00349	CbGpPWpGaD
Chlorpromazine—CHRM3—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00348	0.00348	CbGpPWpGaD
Chlorpromazine—CHRM2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00345	0.00345	CbGpPWpGaD
Chlorpromazine—ADRA1A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00344	0.00344	CbGpPWpGaD
Chlorpromazine—DRD2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00324	0.00324	CbGpPWpGaD
Chlorpromazine—ADRA2A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00319	0.00319	CbGpPWpGaD
Chlorpromazine—HTR2A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00319	0.00319	CbGpPWpGaD
Chlorpromazine—HRH1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00318	0.00318	CbGpPWpGaD
Chlorpromazine—CHRM1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00317	0.00317	CbGpPWpGaD
Chlorpromazine—CHRM3—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00316	0.00316	CbGpPWpGaD
Chlorpromazine—CHRM2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00313	0.00313	CbGpPWpGaD
Chlorpromazine—ADRA1A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00312	0.00312	CbGpPWpGaD
Chlorpromazine—HTR6—Signaling Pathways—CXCL11—nasal cavity cancer	0.00295	0.00295	CbGpPWpGaD
Chlorpromazine—HTR7—Signaling Pathways—CXCL11—nasal cavity cancer	0.00294	0.00294	CbGpPWpGaD
Chlorpromazine—HRH4—Signaling Pathways—FRS2—nasal cavity cancer	0.00292	0.00292	CbGpPWpGaD
Chlorpromazine—ADRA2A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0029	0.0029	CbGpPWpGaD
Chlorpromazine—DRD4—Signaling Pathways—CXCL11—nasal cavity cancer	0.00282	0.00282	CbGpPWpGaD
Chlorpromazine—HTR2B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00269	0.00269	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00265	0.00265	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00256	0.00256	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00256	0.00256	CbGpPWpGaD
Chlorpromazine—DRD1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00254	0.00254	CbGpPWpGaD
Chlorpromazine—DRD3—Signaling Pathways—CXCL11—nasal cavity cancer	0.0025	0.0025	CbGpPWpGaD
Chlorpromazine—CALM3—Innate Immune System—FRS2—nasal cavity cancer	0.00245	0.00245	CbGpPWpGaD
Chlorpromazine—CALM1—Innate Immune System—FRS2—nasal cavity cancer	0.00237	0.00237	CbGpPWpGaD
Chlorpromazine—CALM2—Innate Immune System—FRS2—nasal cavity cancer	0.00237	0.00237	CbGpPWpGaD
Chlorpromazine—CALM3—Adaptive Immune System—FRS2—nasal cavity cancer	0.00235	0.00235	CbGpPWpGaD
Chlorpromazine—CALM1—Adaptive Immune System—FRS2—nasal cavity cancer	0.00227	0.00227	CbGpPWpGaD
Chlorpromazine—CALM2—Adaptive Immune System—FRS2—nasal cavity cancer	0.00227	0.00227	CbGpPWpGaD
Chlorpromazine—DRD5—Signaling Pathways—FRS2—nasal cavity cancer	0.00225	0.00225	CbGpPWpGaD
Chlorpromazine—HTR1A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00218	0.00218	CbGpPWpGaD
Chlorpromazine—HTR2C—Signaling Pathways—CXCL11—nasal cavity cancer	0.00217	0.00217	CbGpPWpGaD
Chlorpromazine—ADRA1B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00208	0.00208	CbGpPWpGaD
Chlorpromazine—DRD2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00191	0.00191	CbGpPWpGaD
Chlorpromazine—HTR2A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00188	0.00188	CbGpPWpGaD
Chlorpromazine—HRH1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00188	0.00188	CbGpPWpGaD
Chlorpromazine—CHRM1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00187	0.00187	CbGpPWpGaD
Chlorpromazine—CHRM3—Signaling Pathways—CXCL11—nasal cavity cancer	0.00187	0.00187	CbGpPWpGaD
Chlorpromazine—CHRM2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00185	0.00185	CbGpPWpGaD
Chlorpromazine—ADRA1A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00184	0.00184	CbGpPWpGaD
Chlorpromazine—HTR6—Signaling Pathways—FRS2—nasal cavity cancer	0.00174	0.00174	CbGpPWpGaD
Chlorpromazine—HTR7—Signaling Pathways—FRS2—nasal cavity cancer	0.00173	0.00173	CbGpPWpGaD
Chlorpromazine—ADRA2A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00171	0.00171	CbGpPWpGaD
Chlorpromazine—DRD4—Signaling Pathways—FRS2—nasal cavity cancer	0.00166	0.00166	CbGpPWpGaD
Chlorpromazine—HTR2B—Signaling Pathways—FRS2—nasal cavity cancer	0.00158	0.00158	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling Pathways—CXCL11—nasal cavity cancer	0.00156	0.00156	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00151	0.00151	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00151	0.00151	CbGpPWpGaD
Chlorpromazine—DRD1—Signaling Pathways—FRS2—nasal cavity cancer	0.00149	0.00149	CbGpPWpGaD
Chlorpromazine—DRD3—Signaling Pathways—FRS2—nasal cavity cancer	0.00147	0.00147	CbGpPWpGaD
Chlorpromazine—CALM3—Immune System—FRS2—nasal cavity cancer	0.00143	0.00143	CbGpPWpGaD
Chlorpromazine—CALM2—Immune System—FRS2—nasal cavity cancer	0.00138	0.00138	CbGpPWpGaD
Chlorpromazine—CALM1—Immune System—FRS2—nasal cavity cancer	0.00138	0.00138	CbGpPWpGaD
Chlorpromazine—CALM3—Disease—FRS2—nasal cavity cancer	0.00132	0.00132	CbGpPWpGaD
Chlorpromazine—HTR1A—Signaling Pathways—FRS2—nasal cavity cancer	0.00128	0.00128	CbGpPWpGaD
Chlorpromazine—HTR2C—Signaling Pathways—FRS2—nasal cavity cancer	0.00128	0.00128	CbGpPWpGaD
Chlorpromazine—CALM2—Disease—FRS2—nasal cavity cancer	0.00127	0.00127	CbGpPWpGaD
Chlorpromazine—CALM1—Disease—FRS2—nasal cavity cancer	0.00127	0.00127	CbGpPWpGaD
Chlorpromazine—ADRA1B—Signaling Pathways—FRS2—nasal cavity cancer	0.00122	0.00122	CbGpPWpGaD
Chlorpromazine—DRD2—Signaling Pathways—FRS2—nasal cavity cancer	0.00113	0.00113	CbGpPWpGaD
Chlorpromazine—HTR2A—Signaling Pathways—FRS2—nasal cavity cancer	0.00111	0.00111	CbGpPWpGaD
Chlorpromazine—HRH1—Signaling Pathways—FRS2—nasal cavity cancer	0.00111	0.00111	CbGpPWpGaD
Chlorpromazine—CHRM1—Signaling Pathways—FRS2—nasal cavity cancer	0.0011	0.0011	CbGpPWpGaD
Chlorpromazine—CHRM3—Signaling Pathways—FRS2—nasal cavity cancer	0.0011	0.0011	CbGpPWpGaD
Chlorpromazine—CHRM2—Signaling Pathways—FRS2—nasal cavity cancer	0.00109	0.00109	CbGpPWpGaD
Chlorpromazine—ADRA1A—Signaling Pathways—FRS2—nasal cavity cancer	0.00109	0.00109	CbGpPWpGaD
Chlorpromazine—ADRA2A—Signaling Pathways—FRS2—nasal cavity cancer	0.00101	0.00101	CbGpPWpGaD
Chlorpromazine—CALM3—Signaling Pathways—FRS2—nasal cavity cancer	0.000921	0.000921	CbGpPWpGaD
Chlorpromazine—CALM2—Signaling Pathways—FRS2—nasal cavity cancer	0.000891	0.000891	CbGpPWpGaD
Chlorpromazine—CALM1—Signaling Pathways—FRS2—nasal cavity cancer	0.000891	0.000891	CbGpPWpGaD
